Your browser is no longer supported. Please, upgrade your browser.
Settings
CRSP CRISPR Therapeutics AG daily Stock Chart
CRSP [NASD]
CRISPR Therapeutics AG
Index- P/E- EPS (ttm)-3.74 Insider Own2.20% Shs Outstand54.12M Perf Week0.91%
Market Cap2.34B Forward P/E- EPS next Y-4.14 Insider Trans-17.33% Shs Float31.27M Perf Month11.90%
Income-185.10M PEG- EPS next Q-0.92 Inst Own50.20% Short Float17.43% Perf Quarter11.98%
Sales2.10M P/S1115.13 EPS this Y-101.60% Inst Trans16.70% Short Ratio10.18 Perf Half Y18.94%
Book/sh7.29 P/B5.94 EPS next Y-11.90% ROA-39.80% Target Price55.75 Perf Year-24.09%
Cash/sh8.08 P/C5.35 EPS next 5Y- ROE-50.90% 52W Range22.22 - 66.72 Perf YTD51.45%
Dividend- P/FCF- EPS past 5Y- ROI-40.70% 52W High-35.15% Beta-
Dividend %- Quick Ratio15.80 Sales past 5Y- Gross Margin- 52W Low94.73% ATR2.05
Employees188 Current Ratio15.80 Sales Q/Q-78.60% Oper. Margin- RSI (14)62.35 Volatility4.94% 4.21%
OptionableYes Debt/Eq0.00 EPS Q/Q-50.60% Profit Margin- Rel Volume0.65 Prev Close44.26
ShortableYes LT Debt/Eq0.00 EarningsJul 29 BMO Payout- Avg Volume535.48K Price43.27
Recom2.50 SMA2010.90% SMA5011.20% SMA20014.91% Volume347,292 Change-2.24%
Jun-10-19Initiated ROTH Capital Buy $50
Apr-12-19Initiated Evercore ISI Outperform
Mar-14-19Initiated William Blair Mkt Perform
Jan-28-19Downgrade Goldman Buy → Neutral
Jan-22-19Downgrade Citigroup Neutral → Sell
Nov-30-18Initiated Needham Buy $62
Oct-10-18Initiated Wells Fargo Outperform $65
Oct-10-18Initiated Guggenheim Neutral
Sep-21-18Initiated Raymond James Underperform
May-15-18Reiterated Chardan Capital Markets Buy $25 → $72.50
Apr-06-18Initiated Goldman Buy $86
Mar-08-18Initiated JMP Securities Mkt Outperform $69
Jan-23-18Upgrade SunTrust Hold → Buy
Dec-22-17Initiated Piper Jaffray Overweight
Jul-14-17Initiated SunTrust Hold $16
Mar-28-17Initiated Chardan Capital Markets Buy $23.50
Jun-13-19 01:43PM  J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB -- Moody's assigns definitive ratings to six CMBS classes of J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB Moody's
10:47AM  Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray American City Business Journals
Jun-12-19 09:27AM  Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash Zacks
Jun-11-19 06:00AM  Is the Newest Gene Editing Stock a Buy? Motley Fool
Jun-10-19 09:29AM  CRISPR Therapeutics Up on Collaboration Expansion by Vertex Zacks
Jun-09-19 07:27AM  Gene Therapy vs. Gene Editing: Which Is Better for Tackling Muscular Dystrophy? Motley Fool
Jun-07-19 09:54AM  Vertex Signs Gene Editing Deals With Crispr, Exonics Worth Up To $2 Billion Benzinga +15.11%
09:54AM  Vertex Pharmaceuticals Bets on Gene Therapy With New Acquisition Barrons.com
09:24AM  Vertex Expands Collaboration With CRISPR, Acquires Exonics Zacks
07:24AM  The Daily Biotech Pulse: Vertex Bets Big On Gene-Editing Therapies, Sanofi Poaches Novartis For CEO Role, Relief In Europe for Endologix Benzinga
Jun-06-19 06:10PM  Vertex enters Duchenne field with $245M buy of Exonics American City Business Journals
05:12PM  Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics Business Wire
May-31-19 08:25AM  Vertex Selects Triple Combo Regimen for Regulatory Submission Zacks
May-30-19 02:36PM  3 Top Gene Therapy Stocks That Could Soar InvestorPlace
May-29-19 07:55PM  J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB -- Moody's assigns a provisional rating to One CMBS class of J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB Moody's
07:00AM  CRISPR Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
May-28-19 03:56PM  J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB -- Moody's assigns provisional ratings to six CMBS classes of J.P. Morgan Chase Commercial Mortgage Securities Trust 2019-OSB Moody's
May-24-19 12:23PM  Highlights from CNBC's Healthy Returns conference CNBC
May-23-19 11:44AM  Genetics, CRISPR and Medical Ethics: CEO of Synthego, CRISPR Therapeutics and Stanford Medical's Hurlbut at Healthy Returns CNBC Videos -5.18%
May-21-19 05:22PM  'We as a species need to come to terms' with CRISPR technology as China awaits birth of third genetically modified baby CNBC
May-13-19 09:27AM  5 Growthy Biotech Stocks to Buy Despite the Scrutiny InvestorPlace -7.00%
May-08-19 08:27AM  Why CRISPR Therapeutics Gained 13.4% in April Motley Fool
May-01-19 07:40PM  Did Hedge Funds Drop The Ball On CRISPR Therapeutics AG (CRSP)? Insider Monkey
11:46AM  Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates Zacks
07:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Apr-29-19 04:01PM  CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-27-19 01:00PM  Better Buy: Editas Medicine vs. CRISPR Therapeutics Motley Fool
Apr-24-19 04:32PM  What's in Store for Vertex (VRTX) This Earnings Season? Zacks
09:26AM  Some CRISPR Therapeutics (NASDAQ:CRSP) Shareholders Are Down 19% Simply Wall St.
Apr-23-19 08:44AM  2 Best Biotech Buyout Plays Motley Fool
Apr-17-19 01:10PM  One-Size-Fits-All CRISPR Lock Could Catapult the Sector Forward GuruFocus.com -6.78%
07:14AM  Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag Zacks
Apr-16-19 02:18PM  CRISPR Therapeutics Attempts Breakout on FDA Fast Track Investopedia +5.20%
11:19AM  UPenn Treats First Cancer Patients in Crispr-Based Trial Bloomberg
07:00AM  CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia GlobeNewswire
Apr-15-19 02:00PM  Four Companies Could Power The New Genomics ETF ETF Trends
Apr-03-19 09:15AM  Stocks Hold Onto Gains in Quiet Session Zacks
Apr-01-19 07:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Mar-28-19 08:19AM  Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics Motley Fool
Mar-27-19 01:13PM  8 Genomic Testing Stocks That Can Ease the Sting of Theranos InvestorPlace
Mar-26-19 06:07PM  3 Top Small-Cap Stocks to Buy Right Now Motley Fool
Mar-21-19 06:13AM  Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons InvestorPlace
06:00AM  CRISPR and Vertex- Front-Runners in Gene-Therapy MoneyShow
Mar-07-19 02:47PM  5 Top Gene-Editing Stocks for 2019 Motley Fool
10:49AM  Has CRISPR Therapeutics AG (NASDAQ:CRSP) Got Enough Cash? Simply Wall St.
Mar-06-19 07:00AM  CRISPR Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire -6.07%
Mar-04-19 11:36AM  Why NOW Is the Time to Buy Gene Therapy Stocks InvestorPlace
09:15AM  S&P Reclaims 2800; NASDAQs Streak Hits 10 Weeks Zacks
Feb-27-19 04:53PM  CRISPR Therapeutics Announces Presentations at the American Association for Cancer Research 2019 Annual Meeting GlobeNewswire
09:58AM  CRISPR Therapeutics Rallies as Gene Stocks Get Hot Again InvestorPlace
Feb-26-19 11:15AM  Biotech ETFs Jump on Roche-Spark Deal Zacks -8.70%
10:54AM  CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study Zacks
09:15AM  Deal on the Way Now that Deadline is Delayed? Zacks
Feb-25-19 04:31PM  Why Danaher, CRISPR Therapeutics, and Clementia Pharmaceuticals Jumped Today Motley Fool +25.20%
04:12PM  Biotech Stocks Pop After This Company Used CRISPR Drug In A Patient Investor's Business Daily
02:21PM  Here's Why Gene Therapy Stocks Are Soaring Today Motley Fool
10:11AM  Crispr Infuses First Human in Landmark Gene-Editing Study Bloomberg
08:02AM  CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
08:00AM  CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 GlobeNewswire
12:58AM  [$$] Crispr Therapeutics treats its first human with gene editing Financial Times
Feb-23-19 09:15AM  Strong Friday Close Secures a 9th Week in the Green Zacks
Feb-21-19 07:00AM  CRISPR Therapeutics Proposes New Members to the Board of Directors GlobeNewswire
Feb-19-19 07:00AM  CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement GlobeNewswire
Feb-14-19 12:01PM  Is Moderna a Buy? Motley Fool
Feb-12-19 07:49AM  Jim Cramer Gives His Opinion On Cronos, Etsy And More Benzinga
Feb-11-19 12:36PM  Here's Why CRISPR Therapeutics Rose 13.5% in January Motley Fool
Feb-09-19 10:03AM  Should Sangamo's Failure Make CRISPR Investors Nervous? Motley Fool
Feb-07-19 03:33PM  Vertex Pharmaceuticals: New Drug, Same Great Growth Story Motley Fool -8.73%
Feb-06-19 10:31AM  Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales Zacks
Feb-05-19 06:00AM  Why Even a Pessimistic Analyst Thinks CRISPR Therapeutics Will Jump 20% Motley Fool
Feb-03-19 02:04PM  3 Gene Therapy Stocks With Huge Catalysts in 2019 Motley Fool
Feb-01-19 01:53PM  3 Biotech Stocks That Are Set for a Breakthrough InvestorPlace
Jan-30-19 10:02AM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
Jan-28-19 04:16PM  CRISPR Stocks Flattened After 1 Downgraded Amid Steep Rivalry Investor's Business Daily -6.11%
09:33AM  Goldman Sachs Steps To The Sidelines On Crispr Therapeutics Benzinga
Jan-24-19 10:46AM  Vertex Terminates COO Ian Smith on Code of Conduct Violation Zacks
Jan-23-19 08:18AM  Better Buy: CRISPR Therapeutics vs. Editas Medicine Motley Fool -5.08%
Jan-22-19 06:55PM  Should You Sell CRISPR Therapeutics Following an Analyst Downgrade? Motley Fool -10.91%
11:50AM  Here's Why CRISPR Therapeutics Stock Fell Today Motley Fool
07:00AM  CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies GlobeNewswire
Jan-19-19 05:55PM  Could CRISPR Therapeutics Be a Millionaire-Maker Stock? Motley Fool
Jan-18-19 12:55PM  4 Gene-Editing Technologies That Could Replace CRISPR Motley Fool
Jan-12-19 12:00PM  Where Will CRISPR Therapeutics Be in 10 Years? Motley Fool
Jan-11-19 04:14PM  Why This IBD Stock Of The Day Broke Out Despite Biotech Turbulence Investor's Business Daily
Jan-10-19 03:36PM  The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29% Motley Fool -5.88%
08:15AM  4 Reasons Editas Medicine's Future Looks Really Bright Motley Fool
Jan-09-19 11:21AM  CRISPR cadre: Check out the 12 Mass. companies exploring gene editing American City Business Journals +8.00%
09:15AM  Market's Newfound Optimism Brings Another 1% Gain Zacks
Jan-07-19 10:03AM  Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag Zacks +13.05%
08:23AM  Here's Why CRISPR Therapeutics Tanked 25.5% in December Motley Fool
Jan-06-19 09:09AM  Better Buy: CRISPR Therapeutics vs. Vertex Pharmaceuticals Motley Fool
Jan-04-19 05:11PM  What Happened in the Stock Market Today Motley Fool +8.03%
04:24PM  These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy Investor's Business Daily
07:00AM  CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease GlobeNewswire
Jan-03-19 10:33AM  Vertex teams up with Feng Zhang startup on gene editing tech American City Business Journals -6.19%
Dec-31-18 11:42AM  Dow Rises 91 Points Because Everybodys Ready for a New Year Barrons.com +6.80%
Dec-27-18 12:27PM  3 Gene Therapy Stocks to Play Biotechs Future InvestorPlace
09:15AM  Christmas Comes a Day Late Zacks
Dec-24-18 09:37AM  Don't Miss Chinese Biotechs Motley Fool +7.44%
Dec-21-18 11:25AM  Did Chinas Designer Babies Just Open Pandoras Box? Motley Fool -17.10%
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a revolutionary gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, the company engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, duchenne muscular dystrophy, cystic fibrosis, and hurler syndrome. It partners with biopharma companies, academic centers, universities, and other organizations. The company has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to develop and commercialize products for the treatment of Duchenne M. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novak RodgerPresidentJun 10Sale45.0050,0002,250,000898,007Jun 12 04:16 PM
Kulkarni SamarthChief Executive OfficerApr 29Option Exercise1.8120,00036,200186,542May 01 04:05 PM
Kulkarni SamarthChief Executive OfficerApr 29Sale42.0320,000840,600166,542May 01 04:05 PM
Novak RodgerPresidentMar 04Sale40.4576,5273,095,240948,007Mar 05 05:59 PM
Novak RodgerPresidentMar 01Sale40.018,693347,7961,024,534Mar 05 05:59 PM
Novak RodgerPresidentFeb 25Sale40.0014,780591,2331,033,227Feb 27 04:10 PM
Novak RodgerPresidentJan 09Sale35.0182,6902,894,9771,048,007Jan 10 04:09 PM
Novak RodgerPresidentJan 08Sale35.0917,310607,4081,130,697Jan 10 04:09 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 27Buy24.9527,461685,1165,380,940Dec 28 04:34 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 26Buy24.8912,737317,0775,353,479Dec 28 04:34 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 24Buy24.5868,0001,671,4825,340,742Dec 26 04:35 PM
Vertex Pharmaceuticals (Europe10% OwnerDec 21Buy22.5822,742513,4785,272,742Dec 26 04:35 PM
EMSTER KURT VONDirectorDec 18Sale29.7069,9252,077,1011,164,268Dec 19 04:22 PM
EMSTER KURT VONDirectorDec 17Sale33.173,00999,7971,234,193Dec 19 04:22 PM
Kulkarni SamarthChief Executive OfficerDec 07Option Exercise1.8121,50038,915167,290Dec 11 04:29 PM
CELGENE CORP /DE/10% OwnerNov 21Sale19.2580,0001,540,0004,173,019Dec 07 09:57 AM
CAGNONI PABLO JDirectorJul 05Option Exercise5.591,6849,4141,684Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 05Sale62.001,684104,4080Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 03Option Exercise5.595,81632,5115,816Jul 05 06:25 PM
CAGNONI PABLO JDirectorJul 03Sale62.005,816360,5920Jul 05 06:25 PM